These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38973543)

  • 1. Impacts of rifaximin and midodrine on morbidity, mortality, and quality of life in patients with decompensated liver cirrhosis.
    Elsabaawy MM; Assem M; Badran H; Mahmoud A; Elsabaawy D; Ragab A
    Eur J Gastroenterol Hepatol; 2024 Aug; 36(8):1022-1028. PubMed ID: 38973543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival.
    Hanafy AS; Hassaneen AM
    Eur J Gastroenterol Hepatol; 2016 Dec; 28(12):1455-1461. PubMed ID: 27622998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study.
    Lv XY; Ding HG; Zheng JF; Fan CL; Li L
    World J Gastroenterol; 2020 Jan; 26(2):199-218. PubMed ID: 31988585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis.
    Vlachogiannakos J; Viazis N; Vasianopoulou P; Vafiadis I; Karamanolis DG; Ladas SD
    J Gastroenterol Hepatol; 2013 Mar; 28(3):450-5. PubMed ID: 23216382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis.
    Hanouneh MA; Hanouneh IA; Hashash JG; Law R; Esfeh JM; Lopez R; Hazratjee N; Smith T; Zein NN
    J Clin Gastroenterol; 2012 Sep; 46(8):709-15. PubMed ID: 22878533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of sleep architecture parameters in cirrhotic patients with recurrent hepatic encephalopathy with the use of rifaximin.
    Bruyneel M; Sersté T; Libert W; van den Broecke S; Ameye L; Dachy B; Mulkay JP; Moreno C; Gustot T
    Eur J Gastroenterol Hepatol; 2017 Mar; 29(3):302-308. PubMed ID: 27977438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial.
    Kimer N; Pedersen JS; Busk TM; Gluud LL; Hobolth L; Krag A; Møller S; Bendtsen F;
    Hepatology; 2017 Feb; 65(2):592-603. PubMed ID: 27775818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
    Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
    Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis.
    Elfert A; Abo Ali L; Soliman S; Ibrahim S; Abd-Elsalam S
    Eur J Gastroenterol Hepatol; 2016 Dec; 28(12):1450-1454. PubMed ID: 27512927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study.
    Rai N; Singh B; Singh A; Vijayvergiya R; Sharma N; Bhalla A; Singh V
    Liver Int; 2017 Mar; 37(3):406-414. PubMed ID: 27614145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care.
    Bohra A; Worland T; Hui S; Terbah R; Farrell A; Robertson M
    World J Gastroenterol; 2020 May; 26(18):2221-2231. PubMed ID: 32476788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotics With or Without Rifaximin for Acute Hepatic Encephalopathy in Critically Ill Patients With Cirrhosis: A Double-Blind, Randomized Controlled (ARiE) Trial.
    Kulkarni AV; Avadhanam M; Karandikar P; Rakam K; Gupta A; Simhadri V; Premkumar M; Zuberi AA; Gujjarlapudi D; Narendran R; Shaik S; Sharma M; Iyengar S; Alla M; Venishetty S; Reddy DN; Rao PN
    Am J Gastroenterol; 2024 May; 119(5):864-874. PubMed ID: 37942950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites.
    Lutz P; Parcina M; Bekeredjian-Ding I; Nischalke HD; Nattermann J; Sauerbruch T; Hoerauf A; Strassburg CP; Spengler U
    PLoS One; 2014; 9(4):e93909. PubMed ID: 24714550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral midodrine is comparable to albumin infusion in cirrhotic patients with refractory ascites undergoing large-volume paracentesis: results of a pilot study.
    Yosry A; Soliman ZA; Eletreby R; Hamza I; Ismail A; Elkady MA
    Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):345-351. PubMed ID: 30312183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis.
    Dong T; Aronsohn A; Gautham Reddy K; Te HS
    Dig Dis Sci; 2016 Dec; 61(12):3621-3626. PubMed ID: 27655104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial.
    Solà E; Solé C; Simón-Talero M; Martín-Llahí M; Castellote J; Garcia-Martínez R; Moreira R; Torrens M; Márquez F; Fabrellas N; de Prada G; Huelin P; Lopez Benaiges E; Ventura M; Manríquez M; Nazar A; Ariza X; Suñé P; Graupera I; Pose E; Colmenero J; Pavesi M; Guevara M; Navasa M; Xiol X; Córdoba J; Vargas V; Ginès P
    J Hepatol; 2018 Dec; 69(6):1250-1259. PubMed ID: 30138685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Midodrine reduces new-onset acute kidney injury and hyponatremia in children with cirrhosis and ascites awaiting liver transplantation: Results from an open-label RCT.
    Ashritha A; Lal BB; Khanna R; Sood V; Sood AK; Alam S
    J Pediatr Gastroenterol Nutr; 2024 Feb; 78(2):350-359. PubMed ID: 38374552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis.
    Zeng X; Sheng X; Wang PQ; Xin HG; Guo YB; Lin Y; Zhong JW; He CZ; Yin J; Liu TT; Ma WJ; Xiao X; Shi PM; Yuan ZL; Yang L; Ma X; Xu JM; Shen XZ; Yang CQ; Zhu X; Lv NH; Xie WF
    Hepatol Int; 2021 Feb; 15(1):155-165. PubMed ID: 33385299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial).
    Sidhu SS; Goyal O; Mishra BP; Sood A; Chhina RS; Soni RK
    Am J Gastroenterol; 2011 Feb; 106(2):307-16. PubMed ID: 21157444
    [TBL] [Abstract][Full Text] [Related]  

  • 20.  Minimal hepatic encephalopathy in cirrhosis- how long to treat?
    Goyal O; Sidhu SS; Kishore H
    Ann Hepatol; 2017 Jan-Feb 2017; 16(1):115-122. PubMed ID: 28051800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.